Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCOY NASDAQ:GNPX NASDAQ:NCNA NASDAQ:PMCB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCOYDecoy Therapeutics$5.30+14.0%$6.27$4.32▼$415.80$2.47M0.389,750 shs20,452 shsGNPXGenprex$0.79-2.1%$1.37$0.76▼$55.00$8.52M-0.941.22 million shs188,060 shsNCNANuCana$1.98-2.5%$1.92$1.33▼$40.00$8.45M2.1737,647 shs15,127 shsPMCBNuvilex$0.73-3.7%$0.73$0.63▼$1.51$8.16M0.46254,945 shs208,531 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCOYDecoy Therapeutics+5.44%-14.52%-19.97%-48.33%+464,999,900.00%GNPXGenprex-3.05%-4.77%-38.08%-55.28%-93.49%NCNANuCana-6.88%+3.05%-9.78%+1.50%-76.83%PMCBNuvilex-5.52%+9.37%+4.31%+16.65%-28.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCOYDecoy Therapeutics$5.30+14.0%$6.27$4.32▼$415.80$2.47M0.389,750 shs20,452 shsGNPXGenprex$0.79-2.1%$1.37$0.76▼$55.00$8.52M-0.941.22 million shs188,060 shsNCNANuCana$1.98-2.5%$1.92$1.33▼$40.00$8.45M2.1737,647 shs15,127 shsPMCBNuvilex$0.73-3.7%$0.73$0.63▼$1.51$8.16M0.46254,945 shs208,531 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCOYDecoy Therapeutics+5.44%-14.52%-19.97%-48.33%+464,999,900.00%GNPXGenprex-3.05%-4.77%-38.08%-55.28%-93.49%NCNANuCana-6.88%+3.05%-9.78%+1.50%-76.83%PMCBNuvilex-5.52%+9.37%+4.31%+16.65%-28.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCOYDecoy Therapeutics 2.00Hold$30.00466.04% UpsideGNPXGenprex 1.00SellN/AN/ANCNANuCana 1.00SellN/AN/APMCBNuvilex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest DCOY, NCNA, GNPX, and PMCB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/22/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026GNPXGenprex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026NCNANuCana Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PMCBNuvilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCOYDecoy TherapeuticsN/AN/AN/AN/A$7.29 per shareN/AGNPXGenprexN/AN/AN/AN/A$1.60 per shareN/ANCNANuCanaN/AN/AN/AN/A$7.24 per shareN/APMCBNuvilexN/AN/AN/AN/A$7.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCOYDecoy Therapeutics-$12.52M-$106.90N/AN/AN/AN/A-395.42%-193.30%N/AGNPXGenprex-$16.23M-$26.50N/AN/AN/AN/A-247.32%-176.73%N/ANCNANuCana-$38.71M-$2.98N/AN/AN/AN/A-153.61%-116.03%N/APMCBNuvilex$30.66M-$1.12N/AN/AN/AN/A2.13%1.69%7/1/2026 (Estimated)Latest DCOY, NCNA, GNPX, and PMCB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026NCNANuCana-$2.6440-$1.25+$1.3940N/AN/AN/A5/13/2026Q1 2026GNPXGenprexN/A-$0.64N/A-$0.64N/AN/A5/8/2026Q1 2026DCOYDecoy TherapeuticsN/A-$4.18N/A-$4.18N/AN/A3/31/2026Q4 2025DCOYDecoy TherapeuticsN/A$43.10N/A$43.10N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDCOYDecoy TherapeuticsN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCOYDecoy TherapeuticsN/A1.841.84GNPXGenprexN/A5.615.61NCNANuCanaN/A5.485.60PMCBNuvilexN/A12.3312.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCOYDecoy Therapeutics11.88%GNPXGenprex14.05%NCNANuCana44.00%PMCBNuvilex34.24%Insider OwnershipCompanyInsider OwnershipDCOYDecoy Therapeutics0.30%GNPXGenprex0.25%NCNANuCana31.20%PMCBNuvilex10.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCOYDecoy Therapeutics20530,000530,000N/AGNPXGenprex2010.59 million10.56 millionNo DataNCNANuCana304.16 million2.86 millionNot OptionablePMCBNuvilex410.74 million9.56 millionOptionableDCOY, NCNA, GNPX, and PMCB HeadlinesRecent News About These CompaniesInsider Buying: Nuvilex (NASDAQ:PMCB) Director Acquires 20,000 Shares of StockJanuary 8, 2026 | insidertrades.comPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsSeptember 2, 2025 | businesswire.comPharmaCyte Biotech, Inc. Announces Closing of $7 Million FinancingAugust 20, 2025 | businesswire.comPharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing InvestorsAugust 18, 2025 | businesswire.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comPharmaCyte Biotech Inc PMCBDecember 5, 2023 | morningstar.comMWith biotech in a slump, the industry’s job market is upside downNovember 28, 2023 | statnews.comSThe return of biotech’s “bump factor” amid an economic downturnNovember 24, 2023 | statnews.comSPharmaCyte Biotech: Entry Into A Material Definitive Agreement, Other Events, Financial Statements And ExhibitsNovember 18, 2023 | cbonds.comCPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | markets.businessinsider.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechNovember 15, 2023 | finance.yahoo.comBiotech power broker John Maraganore offers advice to the next crop of entrepreneursOctober 23, 2023 | statnews.comSPharmaCyte completes tender offer to purchase sharesJune 15, 2023 | msn.comPharmaCyte Biotech Announces Final Results of Tender OfferJune 15, 2023 | finance.yahoo.comLos Angeles Biotech NewsJune 14, 2023 | bizjournals.comPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareMay 11, 2023 | finance.yahoo.comBiotech ETFs’ Performance Deserves A LookApril 21, 2023 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCOY, NCNA, GNPX, and PMCB Company DescriptionsDecoy Therapeutics NASDAQ:DCOY$5.30 +0.65 (+13.98%) Closing price 03:59 PM EasternExtended Trading$5.46 +0.16 (+3.09%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.Genprex NASDAQ:GNPX$0.79 -0.02 (-2.11%) Closing price 04:00 PM EasternExtended Trading$0.78 -0.01 (-0.63%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.NuCana NASDAQ:NCNA$1.98 -0.05 (-2.46%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.02 (+0.76%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Nuvilex NASDAQ:PMCB$0.73 -0.03 (-3.68%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.03 (+4.23%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
